Dbfetch
ID I17RD_HUMAN Reviewed; 739 AA. AC Q8NFM7; Q2NKP7; Q58EZ7; Q6RVF4; Q6UWI5; Q8N113; Q8NFS0; Q9UFA0; DT 13-SEP-2005, integrated into UniProtKB/Swiss-Prot. DT 20-FEB-2007, sequence version 3. DT 18-JUN-2025, entry version 170. DE RecName: Full=Interleukin-17 receptor D; DE Short=IL-17 receptor D; DE Short=IL-17RD; DE AltName: Full=IL17Rhom; DE AltName: Full=Interleukin-17 receptor-like protein; DE AltName: Full=Sef homolog; DE Short=hSef; DE Flags: Precursor; GN Name=IL17RD; Synonyms=IL17RLM, SEF; ORFNames=UNQ6115/PRO20026; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), VARIANT MET-255, FUNCTION, RP AND INTERACTION WITH FGFR1 AND FGFR2. RX PubMed=12958313; DOI=10.1074/jbc.m306936200; RA Xiong S.Q., Zhao Q.H., Rong Z., Huang G.R., Huang Y., Chen P.L., Zhang S., RA Liu L., Chang Z.J.; RT "hSef inhibits PC-12 cell differentiation by interfering with Ras-mitogen- RT activated protein kinase MAPK signaling."; RL J. Biol. Chem. 278:50273-50282(2003). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), VARIANT MET-255, AND SUBCELLULAR RP LOCATION. RC TISSUE=Testis; RX PubMed=14742870; DOI=10.1073/pnas.0307952100; RA Preger E., Ziv I., Shabtay A., Sher I., Tsang M., Dawid I.B., Altuvia Y., RA Ron D.; RT "Alternative splicing generates an isoform of the human Sef gene with RT altered subcellular localization and specificity."; RL Proc. Natl. Acad. Sci. U.S.A. 101:1229-1234(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-255. RA Gilbert J.M., Gorman D.M.; RT "Identification of novel IL-17 related receptors."; RL Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT MET-255. RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT MET-255. RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANT MET-255. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION, TISSUE SPECIFICITY, HOMOOLIGOMERIZATION, AND INTERACTION WITH RP FGFR1. RX PubMed=12807873; DOI=10.1074/jbc.m305022200; RA Yang R.-B., Domingos Ng C.K., Wasserman S.M., Koemueves L.G., RA Gerritsen M.E., Topper J.N.; RT "A novel interleukin-17 receptor-like protein identified in human umbilical RT vein endothelial cells antagonizes basic fibroblast growth factor-induced RT signaling."; RL J. Biol. Chem. 278:33232-33238(2003). RN [8] RP FUNCTION, INTERACTION WITH MAP2K1/2, AND IDENTIFICATION IN A COMPLEX WITH RP MAP2K1/2 AND MAPK1/3. RX PubMed=15239952; DOI=10.1016/j.devcel.2004.05.019; RA Torii S., Kusakabe M., Yamamoto T., Maekawa M., Nishida E.; RT "Sef is a spatial regulator for Ras/MAP kinase signaling."; RL Dev. Cell 7:33-44(2004). RN [9] RP VARIANTS HH18 THR-131; ARG-162; SER-306; CYS-379; LEU-468; GLN-577 AND RP VAL-735, AND CHARACTERIZATION OF VARIANTS HH18 THR-131; ARG-162; SER-306; RP CYS-379; LEU-468; GLN-577 AND VAL-735. RX PubMed=23643382; DOI=10.1016/j.ajhg.2013.04.008; RA Miraoui H., Dwyer A.A., Sykiotis G.P., Plummer L., Chung W., Feng B., RA Beenken A., Clarke J., Pers T.H., Dworzynski P., Keefe K., Niedziela M., RA Raivio T., Crowley W.F. Jr., Seminara S.B., Quinton R., Hughes V.A., RA Kumanov P., Young J., Yialamas M.A., Hall J.E., Van Vliet G., RA Chanoine J.P., Rubenstein J., Mohammadi M., Tsai P.S., Sidis Y., Lage K., RA Pitteloud N.; RT "Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in RT individuals with congenital hypogonadotropic hypogonadism."; RL Am. J. Hum. Genet. 92:725-743(2013). CC -!- FUNCTION: Feedback inhibitor of fibroblast growth factor mediated Ras- CC MAPK signaling and ERK activation (PubMed:12807873, PubMed:12958313). CC Regulates the nuclear ERK signaling pathway by spatially blocking CC nuclear translocation of activated ERK without inhibiting cytoplasmic CC phosphorylation of ERK (PubMed:15239952). Mediates JNK activation and CC may be involved in apoptosis (By similarity). May inhibit FGF-induced CC FGFR1 tyrosine phosphorylation (By similarity). Might have a role in CC the early stages of fate specification of GnRH-secreting neurons (By CC similarity). Inhibits TGFB-induced epithelial-to-mesenchymal transition CC in lens epithelial cells (By similarity). CC {ECO:0000250|UniProtKB:Q8JZL1, ECO:0000269|PubMed:12807873, CC ECO:0000269|PubMed:12958313, ECO:0000269|PubMed:15239952}. CC -!- SUBUNIT: Interacts with MAP3K7 (By similarity). Self-associates. CC Interacts with FGFR1, FGFR2 and phosphorylated MAP2K1 or MAP2K2. CC Associates with a MAP2K1/2-MAPK1/3 complex. {ECO:0000250, CC ECO:0000269|PubMed:12807873, ECO:0000269|PubMed:12958313, CC ECO:0000269|PubMed:15239952}. CC -!- INTERACTION: CC Q8NFM7; Q9NYV6: RRN3; NbExp=2; IntAct=EBI-20809393, EBI-2510653; CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane CC {ECO:0000269|PubMed:14742870}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:14742870}. Cell membrane CC {ECO:0000269|PubMed:14742870}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:14742870}. Note=Predominantly associated with the CC Golgi apparatus and is partially translocated to the plasma membrane CC upon stimulation. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=hSef-a, IL17RLM-L, Long; CC IsoId=Q8NFM7-1; Sequence=Displayed; CC Name=2; Synonyms=IL17RLM-S, Short; CC IsoId=Q8NFM7-2; Sequence=VSP_015582; CC Name=3; CC IsoId=Q8NFM7-3; Sequence=VSP_015583; CC Name=4; Synonyms=hSef-b; CC IsoId=Q8NFM7-4; Sequence=VSP_015584; CC -!- TISSUE SPECIFICITY: Expressed in umbilical vein endothelial cells and CC in several highly vascularized tissues such as kidney, colon, skeletal CC muscle, heart and small intestine. Highly expressed in ductal CC epithelial cells of salivary glands, seminal vesicles and the CC collecting tubules of the kidney. Isoform 1 is also highly expressed in CC both fetal and adult brain, pituitary, tonsils, spleen, adenoids, fetal CC kidney, liver, testes and ovary. Isoform 1 is also expressed at CC moderate levels in primary aortic endothelial cells and adrenal CC medulla, and at low levels in adrenal cortex. Isoform 4 is specifically CC and highly expressed in pituitary, fetal brain and umbilical vein CC endothelial cells. {ECO:0000269|PubMed:12807873}. CC -!- DISEASE: Hypogonadotropic hypogonadism 18 with or without anosmia CC (HH18) [MIM:615267]: A disorder characterized by absent or incomplete CC sexual maturation by the age of 18 years, in conjunction with low CC levels of circulating gonadotropins and testosterone and no other CC abnormalities of the hypothalamic-pituitary axis. In some cases, it is CC associated with non-reproductive phenotypes, such as anosmia, cleft CC palate, and sensorineural hearing loss. Anosmia or hyposmia is related CC to the absence or hypoplasia of the olfactory bulbs and tracts. CC Hypogonadism is due to deficiency in gonadotropin-releasing hormone and CC probably results from a failure of embryonic migration of gonadotropin- CC releasing hormone-synthesizing neurons. In the presence of anosmia, CC idiopathic hypogonadotropic hypogonadism is referred to as Kallmann CC syndrome, whereas in the presence of a normal sense of smell, it has CC been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH). CC {ECO:0000269|PubMed:23643382}. Note=The disease is caused by variants CC affecting distinct genetic loci, including the gene represented in this CC entry. Some patients carrying mutations in IL17RD also have a CC heterozygous mutation in another HH-associated gene including FGFR1 and CC KISS1R (PubMed:23643382). {ECO:0000269|PubMed:23643382}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF494208; AAM74077.1; -; mRNA. DR EMBL; AF494211; AAM74080.1; -; mRNA. DR EMBL; AY489047; AAS15051.2; -; mRNA. DR EMBL; AF458067; AAM77571.1; -; mRNA. DR EMBL; AY358774; AAQ89134.1; -; mRNA. DR EMBL; AL133097; CAB61408.1; -; mRNA. DR EMBL; AL833913; CAD38769.1; -; mRNA. DR EMBL; BC111702; AAI11703.2; -; mRNA. DR CCDS; CCDS2880.2; -. [Q8NFM7-1] DR CCDS; CCDS82790.1; -. [Q8NFM7-2] DR PIR; T42695; T42695. DR RefSeq; NP_001305793.1; NM_001318864.2. [Q8NFM7-2] DR RefSeq; NP_060033.3; NM_017563.5. [Q8NFM7-1] DR RefSeq; XP_006713272.1; XM_006713209.3. DR RefSeq; XP_011532151.2; XM_011533849.2. [Q8NFM7-2] DR RefSeq; XP_047304325.1; XM_047448369.1. [Q8NFM7-2] DR AlphaFoldDB; Q8NFM7; -. DR SMR; Q8NFM7; -. DR BioGRID; 120132; 27. DR CORUM; Q8NFM7; -. DR FunCoup; Q8NFM7; 610. DR IntAct; Q8NFM7; 6. DR MINT; Q8NFM7; -. DR STRING; 9606.ENSP00000296318; -. DR GlyCosmos; Q8NFM7; 8 sites, No reported glycans. DR GlyGen; Q8NFM7; 8 sites, 3 N-linked glycans (4 sites). DR iPTMnet; Q8NFM7; -. DR PhosphoSitePlus; Q8NFM7; -. DR BioMuta; IL17RD; -. DR DMDM; 126302555; -. DR jPOST; Q8NFM7; -. DR MassIVE; Q8NFM7; -. DR PaxDb; 9606-ENSP00000296318; -. DR PeptideAtlas; Q8NFM7; -. DR ProteomicsDB; 73324; -. [Q8NFM7-1] DR ProteomicsDB; 73325; -. [Q8NFM7-2] DR ProteomicsDB; 73326; -. [Q8NFM7-3] DR ProteomicsDB; 73327; -. [Q8NFM7-4] DR Antibodypedia; 31518; 312 antibodies from 31 providers. DR DNASU; 54756; -. DR Ensembl; ENST00000296318.12; ENSP00000296318.7; ENSG00000144730.19. [Q8NFM7-1] DR Ensembl; ENST00000320057.9; ENSP00000322250.5; ENSG00000144730.19. [Q8NFM7-2] DR Ensembl; ENST00000463523.5; ENSP00000417516.1; ENSG00000144730.19. [Q8NFM7-2] DR GeneID; 54756; -. DR KEGG; hsa:54756; -. DR MANE-Select; ENST00000296318.12; ENSP00000296318.7; NM_017563.5; NP_060033.3. DR UCSC; uc003dil.3; human. [Q8NFM7-1] DR AGR; HGNC:17616; -. DR CTD; 54756; -. DR DisGeNET; 54756; -. DR GeneCards; IL17RD; -. DR GeneReviews; IL17RD; -. DR HGNC; HGNC:17616; IL17RD. DR HPA; ENSG00000144730; Low tissue specificity. DR MalaCards; IL17RD; -. DR MIM; 606807; gene. DR MIM; 615267; phenotype. DR OpenTargets; ENSG00000144730; -. DR Orphanet; 478; Kallmann syndrome. DR VEuPathDB; HostDB:ENSG00000144730; -. DR eggNOG; ENOG502QV61; Eukaryota. DR GeneTree; ENSGT00940000156669; -. DR HOGENOM; CLU_024846_0_0_1; -. DR InParanoid; Q8NFM7; -. DR OMA; KNCKEDQ; -. DR OrthoDB; 9325096at2759; -. DR PAN-GO; Q8NFM7; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q8NFM7; -. DR PathwayCommons; Q8NFM7; -. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR SignaLink; Q8NFM7; -. DR BioGRID-ORCS; 54756; 14 hits in 1148 CRISPR screens. DR ChiTaRS; IL17RD; human. DR GenomeRNAi; 54756; -. DR Pharos; Q8NFM7; Tbio. DR PRO; PR:Q8NFM7; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q8NFM7; protein. DR Bgee; ENSG00000144730; Expressed in secondary oocyte and 173 other cell types or tissues. DR ExpressionAtlas; Q8NFM7; baseline and differential. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0030368; F:interleukin-17 receptor activity; IBA:GO_Central. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; ISS:UniProtKB. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB. DR FunFam; 3.40.50.11530:FF:000003; Interleukin-17 receptor D; 1. DR Gene3D; 3.40.50.11530; -; 1. DR InterPro; IPR039465; IL-17_rcpt-like. DR InterPro; IPR031951; IL17R_D_N. DR InterPro; IPR013568; SEFIR_dom. DR InterPro; IPR035897; Toll_tir_struct_dom_sf. DR PANTHER; PTHR15583; INTERLEUKIN-17 RECEPTOR; 1. DR PANTHER; PTHR15583:SF14; INTERLEUKIN-17 RECEPTOR D; 1. DR Pfam; PF16742; IL17R_D_N; 1. DR Pfam; PF08357; SEFIR; 1. DR SUPFAM; SSF52200; Toll/Interleukin receptor TIR domain; 1. DR PROSITE; PS51534; SEFIR; 1. DR neXtProt; NX_Q8NFM7; -. DR PharmGKB; PA134993407; -. DR TreeFam; TF329644; -. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Cytoplasm; Disease variant; KW Glycoprotein; Golgi apparatus; Hypogonadotropic hypogonadism; KW Kallmann syndrome; Membrane; Proteomics identification; Receptor; KW Reference proteome; Signal; Transmembrane; Transmembrane helix. FT SIGNAL 1..16 FT /evidence="ECO:0000255" FT CHAIN 17..739 FT /note="Interleukin-17 receptor D" FT /id="PRO_0000041871" FT TOPO_DOM 17..299 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 300..320 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 321..739 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 355..509 FT /note="SEFIR" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00867" FT REGION 614..635 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 650..719 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 667..702 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 19 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 55 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 62 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 80 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 137 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 171 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 206 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 277 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..144 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12958313, FT ECO:0000303|PubMed:17974005" FT /id="VSP_015582" FT VAR_SEQ 1..42 FT /note="MAPWLQLCSVFFTVNACLNGSQLAVAAGGSGRARGADTCGWR -> MPRASA FT SGVPALFVSGEQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:12975309" FT /id="VSP_015583" FT VAR_SEQ 1..42 FT /note="MAPWLQLCSVFFTVNACLNGSQLAVAAGGSGRARGADTCGWR -> MDYRQS FT WPWQ (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14742870, FT ECO:0000303|PubMed:15489334" FT /id="VSP_015584" FT VARIANT 131 FT /note="K -> T (in HH18; results in decreased expression at FT the cell surface and reduced activity; dbSNP:rs184758350)" FT /evidence="ECO:0000269|PubMed:23643382" FT /id="VAR_069936" FT VARIANT 162 FT /note="K -> R (in HH18; results in decreased expression at FT the cell surface)" FT /evidence="ECO:0000269|PubMed:23643382" FT /id="VAR_069937" FT VARIANT 255 FT /note="T -> M (in dbSNP:rs6780995)" FT /evidence="ECO:0000269|PubMed:12958313, FT ECO:0000269|PubMed:12975309, ECO:0000269|PubMed:14742870, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005, FT ECO:0000269|Ref.3" FT /id="VAR_023478" FT VARIANT 301 FT /note="V -> M (in dbSNP:rs17057718)" FT /id="VAR_023479" FT VARIANT 306 FT /note="P -> S (in HH18; reduced activity)" FT /evidence="ECO:0000269|PubMed:23643382" FT /id="VAR_069938" FT VARIANT 379 FT /note="Y -> C (in HH18; some patients have a second FT mutation in the HH-associated gene FGFR1; reduced activity; FT dbSNP:rs369641068)" FT /evidence="ECO:0000269|PubMed:23643382" FT /id="VAR_069939" FT VARIANT 468 FT /note="S -> L (in HH18; reduced activity; FT dbSNP:rs145221454)" FT /evidence="ECO:0000269|PubMed:23643382" FT /id="VAR_069940" FT VARIANT 577 FT /note="P -> Q (in HH18; reduced activity; FT dbSNP:rs587776980)" FT /evidence="ECO:0000269|PubMed:23643382" FT /id="VAR_069941" FT VARIANT 735 FT /note="A -> V (in HH18; the patient carries a second FT mutation in the HH-associated gene KISS1R; results in FT decreased expression at the cell surface; FT dbSNP:rs587776979)" FT /evidence="ECO:0000269|PubMed:23643382" FT /id="VAR_069942" FT CONFLICT 223 FT /note="H -> HGSDMQVSFDHAPH (in Ref. 4; CAB61408)" FT /evidence="ECO:0000305" FT CONFLICT 248 FT /note="K -> E (in Ref. 1; AAM74077)" FT /evidence="ECO:0000305" SQ SEQUENCE 739 AA; 82411 MW; 7A2B45818DBD6E44 CRC64; MAPWLQLCSV FFTVNACLNG SQLAVAAGGS GRARGADTCG WRGVGPASRN SGLYNITFKY DNCTTYLNPV GKHVIADAQN ITISQYACHD QVAVTILWSP GALGIEFLKG FRVILEELKS EGRQCQQLIL KDPKQLNSSF KRTGMESQPF LNMKFETDYF VKVVPFPSIK NESNYHPFFF RTRACDLLLQ PDNLACKPFW KPRNLNISQH GSDMQVSFDH APHNFGFRFF YLHYKLKHEG PFKRKTCKQE QTTETTSCLL QNVSPGDYII ELVDDTNTTR KVMHYALKPV HSPWAGPIRA VAITVPLVVI SAFATLFTVM CRKKQQENIY SHLDEESSES STYTAALPRE RLRPRPKVFL CYSSKDGQNH MNVVQCFAYF LQDFCGCEVA LDLWEDFSLC REGQREWVIQ KIHESQFIIV VCSKGMKYFV DKKNYKHKGG GRGSGKGELF LVAVSAIAEK LRQAKQSSSA ALSKFIAVYF DYSCEGDVPG ILDLSTKYRL MDNLPQLCSH LHSRDHGLQE PGQHTRQGSR RNYFRSKSGR SLYVAICNMH QFIDEEPDWF EKQFVPFHPP PLRYREPVLE KFDSGLVLND VMCKPGPESD FCLKVEAAVL GATGPADSQH ESQHGGLDQD GEARPALDGS AALQPLLHTV KAGSPSDMPR DSGIYDSSVP SSELSLPLME GLSTDQTETS SLTESVSSSS GLGEEEPPAL PSKLLSSGSC KADLGCRSYT DELHAVAPL //